Equities Analysts Set Expectations for RVPH FY2026 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at Zacks Research upped their FY2026 earnings per share estimates for shares of Reviva Pharmaceuticals in a research report issued on Wednesday, May 27th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($1.96) for the year, up from their previous estimate of ($2.21). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ FY2027 earnings at ($1.44) EPS.

A number of other research firms have also recently issued reports on RVPH. Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 21st. Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, D. Boral Capital cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.43 on Friday. The stock has a market capitalization of $5.68 million, a price-to-earnings ratio of -0.11 and a beta of 0.75. Reviva Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $23.00. The stock’s fifty day moving average is $0.74 and its two-hundred day moving average is $5.16.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10).

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 1st quarter valued at $58,000. XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals in the second quarter worth about $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the third quarter worth about $37,000. State Street Corp raised its position in Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after acquiring an additional 256,500 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.